SCHEMBL30730644

SCHEMBL30730644

Cc1nonc1CC(=O)N1CCCC(n2nnc(-c3ccc(F)cc3)n2)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.51
ALDH1A1 P00352 2/20 0.49
HSD11B1 P28845 2/20 0.48
GFER P55789 1/20 0.47
EGFR P00533 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
GRM5 P41594 1/20 0.41
CLPP Q16740 1/20 0.41
MAPK1 P28482 2/20 0.40
KCNJ6 P48051 1/20 0.40
KCNJ5 P48544 1/20 0.40
KCNJ3 P48549 1/20 0.40
MAPT P10636 1/20 0.40
NPC1 O15118 1/20 0.39
LMNA P02545 2/20 0.39
TSHR P16473 2/20 0.39
ALOX15 P16050 1/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730585 0.89 LMNA (0.47) PKMALDH1A1GFERKMT2AMEN1
SCHEMBL32676571 0.83 LMNA (0.41) PKMALDH1A1HSD11B1GFERKMT2A
SCHEMBL30730532 0.82 PKM (0.40) PKMALDH1A1GFERSMN1; SMN2KMT2A
SCHEMBL30730663 0.81 PKM (0.44) PKMALDH1A1GFERSMN1; SMN2KMT2A
SCHEMBL32677015 0.81 LMNA (0.40) PKMALDH1A1GFERKMT2AMEN1
SCHEMBL30730610 0.80 GRM5 (0.66) PKMALDH1A1HSD11B1SMN1; SMN2KMT2A
SCHEMBL30730618 0.80 PKM (0.54) PKMALDH1A1HSD11B1GFERSMN1; SMN2
SCHEMBL32676970 0.79 RAB9A (0.50) PKMALDH1A1HSD11B1GFERKMT2A
SCHEMBL30730596 0.79 ENPP2 (0.42) PKMALDH1A1GFERSMN1; SMN2MAPK1
SCHEMBL30730540 0.79 PKM (0.44) PKMALDH1A1HSD11B1GFERKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 PKM 2873/4885ALDH1A1 2154/4885HSD11B1 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.